GRM4 positive allosteric modulators inhibit breast cancer cell proliferation and promote cell apoptosis

李林海; 肖　斌; 郭梓璇

doi:10.19401/j.cnki.1007-3639.2018.08.001

您当前的位置：

首页 >

文章列表页 >

GRM4 positive allosteric modulators inhibit breast cancer cell proliferation and promote cell apoptosis

更新时间：2026-01-27

- GRM4 positive allosteric modulators inhibit breast cancer cell proliferation and promote cell apoptosis
- China Oncology Vol. 28, Issue 8, Pages: 561-566(2018)
- 作者机构：
  
  1. 中国人民解放军广州总医院检验科,广东,广州,510000
  2. 嘉应学院检验系,广东,梅州,514000
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.08.001
  CLC： R737.9
- Published Online：14 September 2018，
  
  Published：14 September 2018
- 稿件说明：
移动端阅览
李林海,肖　斌,郭梓璇,等. GRM4正向别构调节剂抑制乳腺癌细胞的增殖并促进细胞凋亡[J]. 中国癌症杂志, 2018, 28(8): 561-566.

李林海, 肖　斌, 郭梓璇. GRM4 positive allosteric modulators inhibit breast cancer cell proliferation and promote cell apoptosis[J]. China Oncology, 2018, 28(8): 561-566.
李林海,肖　斌,郭梓璇,等. GRM4正向别构调节剂抑制乳腺癌细胞的增殖并促进细胞凋亡[J]. 中国癌症杂志, 2018, 28(8): 561-566. DOI： 10.19401/j.cnki.1007-3639.2018.08.001.

李林海, 肖　斌, 郭梓璇. GRM4 positive allosteric modulators inhibit breast cancer cell proliferation and promote cell apoptosis[J]. China Oncology, 2018, 28(8): 561-566. DOI： 10.19401/j.cnki.1007-3639.2018.08.001.

摘要

背景与目的：代谢型谷氨酸受体4（glutamate metabotropic receptor 4，GRM4）在多种恶性肿瘤中高表达并与肿瘤患者的预后相关，但GRM4在乳腺癌中的生物学作用仍不清楚。本研究拟探讨GRM4的两种正向别构调节剂VU0364439及VU0364770对乳腺癌细胞的增殖及凋亡的影响，进而为乳腺癌的靶向治疗提供思路。方法：在体外培养的乳腺癌细胞系MDA-MB-231、MCF-7和SK-BR-3中分别单独加入VU0364439、VU0364770以及联合使用两种试剂，利用CellTiter-Glo

发光细胞活力测定法定量检测各组乳腺癌细胞系的增殖活性；利用Annexin Ⅴ-PI双染法检测各组乳腺癌细胞系的凋亡水平；通过实时荧光定量聚合酶链反应（realtime fluorescent quantitative polymerase chain reaction，RTFQ-PCR）技术测定GRM4基因在6种乳腺癌细胞系中的表达情况，在GRM4表达水平最高的细胞中单独加入或联合使用VU0364439及VU0364770，用RTFQ-PCR检测GRM4基因表达的改变。结果：与对照组相比，单独使用及联合使用VU0364439及VU0364770显著抑制乳腺癌细胞MCF-7、MDA-MB-231和SK-BR-3的增殖水平，并促进MCF-7细胞凋亡现象的发生；联合使用与单独使用VU0364439及VU0364770对乳腺癌细胞增殖及凋亡的作用差异无统计学意义（P＞0.05）；RTFQ-PCR实验表明GRM4在MCF-7细胞中的表达水平最高；在MCF-7细胞中分别单独使用或联合使用VU0364439及VU0364770均能激活GRM4的表达。结论：GRM4的正向别构调节剂能够抑制乳腺癌细胞增殖并促进细胞凋亡，其作用可能是通过激活GRM4基因的表达引起的，本研究为探索GRM4在乳腺癌中的作用机制以及开发新的乳腺癌靶向治疗方法奠定了基础。

Abstract

Background and purpose: Glutamate metabotropic receptor 4 (GRM4) is highly expressed in many tumors

and its expression is associated w

ith the prognosis of patients. However

the function of GRM4 in breast cancer is still not clear. This study aimed to investigate the effects of positive allosteric modulators VU0364439 and VU0364770 on the proliferation and apoptosis of breast cancer cells

and then provide novel strategies for breast cancer targeted therapy. Methods: VU0364439 and VU0364770 were added solely or in combination into breast cancer cell lines MDA-MB-231

MCF-7 and SK-BR-3. The proliferation activities of these cells were detected using CellTiter- Glo

luminescent cell viability assay. Annexin Ⅴ-PI double staining was used to detect the apoptosis of breast cancer cells. The expressions of GRM4 gene in six breast cancer cell lines were detected using real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR). After VU0364439 and VU0364770 were uesd solely or in combination

the expression of GRM4 gene was detected in the cell line with the highest GRM4 expression. Results: Compared with the control group

the proliferations of breast cancer cells MCF-7

MDA-MB-231 and SK-BR-3 were significantly inhibited after VU0364439 and VU0364770 were added solely or in combination. VU0364439 and VU0364770 also promoted the cell apoptosis of these breast cancer cell lines. The inhibitory effect of VU0364439 and VU0364770 on the proliferation of breast cancer cells was not significantly different when they were used in combination (P0.05). RTFQ-PCR assay showed that the expression of GRM4 was higher in MCF-7 cells. The GRM4 expression could be activated when VU0364439 and VU0364770 were used solely or in combination. Conclusion: GRM4 positive allosteric modulators could inhibit breast cancer cell proliferation and promote cell apoptosis. This biological effect might function by activating GRM4 expression. This study lays the foundation for exploring the effect of GRM4 in breast cancer and developing novel strategies for breast cancer targeted therapy.

关键词

Keywords

references

Views

2174

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

Current status and future perspectives of antibody-drug conjugates in breast cancer therapy

Research advances in estrogen receptor low positive early breast cancer

Progress of important clinical trials of breast cancer in China in 2022

Progress of important clinical research on breast cancer in China in 2025

Related Author

LU Ye

ZHANG Wenxiang

KONG Xiangyi

FANG Yi

WANG Jing

GAO Jidong

Jialin LIN

Wenna WANG

Related Institution

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰